Evidence map›Paper›PMID 34048931›Full record

ArticleInternational journal of pharmaceutics2021

Coupling the in vivo performance to the in vitro characterization of PLGA microparticles.

Andrew Otte, Frederick Damen, Craig Goergen, Kinam Park

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Long-Acting injectable buprenorphine PLGA microparticle formulation.International journal of pharmaceutics · 2025
    Article
  3. Article
  4. PLGA-based long-acting injectable (LAI) formulations.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrew OttePurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA. Electronic address: aotte@purdue.edu.
Frederick DamenPurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.
Craig GoergenPurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.
Kinam ParkPurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA; Purdue University, Department of Pharmaceutics, West Lafayette, IN 47907, USA.

Funding

Injectable naltrexone 2-month depot formulationsUH3DA048774 · NIDA · PURDUE UNIVERSITY · PI PARK, KINAM · 2022 to 2024
$4.9M
Injectable naltrexone 2-month depot formulationsUG3DA048774 · NIDA · PURDUE UNIVERSITY · PI PARK, KINAM · 2019 to 2020
$2.9M
Spatial Analysis of Cardiac Disease using Murine Four-Dimensional UltrasoundF30HL145980 · NHLBI · PURDUE UNIVERSITY · PI DAMEN, FREDERICK W · 2019 to 2021
$141k
NHLBI NIH HHS F30 HL145980NIDA NIH HHS UG3 DA048774NIDA NIH HHS UH3 DA048774
6 · The paper itself

Abstract

The main objective of the study was to determine if rodent housing conditions, specifically housing climate, could impact the in vivo performance of poly(lactide-co-glycolide) (PLGA) microspheres through temperature modification of the subcutaneous space. Vivitrol®, a once monthly naltrexone injectable suspension, was chosen as a model PLGA microparticle formulation for this study. Two lots of Vivitrol were used to ascertain any potential differences that may exist between the batches and if in vitro characterization techniques could delineate any variation(s). The pharmacokinetics of the naltrexone-PLGA microparticles were determined in the rodent model under two different housing climates (20 vs. 25 °C). The results demonstrate that such difference in housing temperature resulted in a change in subcutaneous temperature but actually within a narrow range (36.31-36.77 °C) and thus minimally influenced the in vivo performance of subcutaneously injected microparticles. The shake-flask method was used to characterize the in vitro release at 35, 36, and 37 °C and demonstrated significant differences in the in vitro release profiles across this range of temperatures. Minimal differences in the in vitro characterization of the two lots were found. While these results did not provide statistical significance, the local in vivo temperature may be a parameter that should be considered when evaluating microparticle performance. The IVIVCs demonstrate that in vitro release at 37 °C may not accurately represent the in vivo conditions (i.e., subcutaneous space in rodents), and in certain instances lower in vitro release temperatures may more accurately represent the in vivo microenvironment and provide better correlations. Future studies will determine the extent temperature and specifically co-housing, may have on the relative impact of the in vivo performance of injectable polymeric microparticles based upon the significant differences observed in the in vitro release profiles across the range of 35-37 °C.

Indexed as

Lactic AcidPolyglycolic AcidMicrospheresParticle SizePolylactic Acid-Polyglycolic Acid CopolymerTemperatureLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerIn vivo-in vitro correlationNaltrexonePharmacokineticsPLGA microparticlesVivitrol

Identifiers

PMID34048931
PMCPMC9435463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.